#United States #San Francisco #Phanes Therapeutics #PDAC #Spevatamig

Phanes Therapeutics Showcases Groundbreaking Study Results on Spevatamig

Phanes Therapeutics, Inc., a biotech company at the forefront of oncology innovation, has announced their participation in the upcoming ASCO Gastrointestinal Cancers Symposium in San Francisco, scheduled for January 8-10, 2026. They will present the results from their Phase 1/2 study on Spevatamig (PT886), focusing on its efficacy in combination with chemotherapy as the primary treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).

About the Presentation

During this symposium, Phanes will reveal key insights from their TWINPEAK study, a multi-center trial assessing Spevatamig's safety, pharmacokinetics, and preliminary effectiveness in patients suffering from advanced variations of gastrointestinal cancers, including mPDAC. This presentation marks the first public disclosure of critical clinical data surrounding Spevatamig, a novel therapeutic attempting to make strides in the treatment of a notoriously aggressive form of cancer.

Key Details of the Presentation:

• - Title: Phase 1/2 study of Spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel in frontline treatment of mPDAC
• - Abstract Number: 709
• - Session: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
• - Date and Time: January 9, 2026, from 11:30 AM to 1 PM PST
• - First Author: Anwaar Saeed, MD, University of Pittsburgh Medical Center

About Spevatamig

Spevatamig is a pioneering bispecific antibody that targets both claudin 18.2 and CD47, setting itself apart as a first-in-class therapy with the potential to significantly impact treatment regimens for pancreatic cancer. The FDA has recognized its potential by granting it orphan drug designation and Fast Track status, a testament to Spevatamig's promise in treating patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma. Additionally, in 2023, a collaboration with Merck was established to explore the combination of Spevatamig with Merck’s pembrolizumab, an anti-PD-1 therapy, in enhancing therapeutic outcomes for cancer patients.

Updates on the Trial

The TWINPEAK study (NCT05482893) currently enrolls patients at various sites across the U.S., focusing on advanced gastric, gastroesophageal junction, pancreatic ductal, or biliary tract adenocarcinomas. Phanes is also initiating a Phase 2 version of this trial in China, paving the way for potentially more extensive applications of this treatment across different regions.

About Phanes Therapeutics

Phanes Therapeutics is committed to revolutionizing oncology through its innovative drug discovery and development processes. Beyond Spevatamig, they are conducting other Phase 1/2 trials, including studies for their promising monoclonal antibody, Mavrostobart, and Peluntamig, both of which have similarly received orphan drug designations and Fast Track designations by the FDA. Phanes utilizes unique technology platforms such as PACbody®, SPECpair®, and ATACCbody® to enhance drug stability and effectiveness, demonstrating their commitment to pushing the boundaries of cancer therapy.

As they prepare for their moment on stage at ASCO GI 2026, the results from Phanes Therapeutics signify a hopeful advancement in the treatment of aggressive forms of cancer. Enthusiasm builds as stakeholders, healthcare professionals, and patients eagerly await further developments in their groundbreaking research.